Scientific Online Resource System

Social Medicine

Course of COVID-19 infection in hospitalized patients with diabetes mellitus - own experience

Dilyana Stoyanova, Nikola Kostadinov, Vladimir Gonchev


Introduction: Infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is more severe in patients with diabetes mellitus (DM), especially in cases of type 2 diabetes (DMT2) - due to their older age, the high frequency of metabolic syndrome and related cardiovascular diseases (arterial hypertension, heart failure, ischemic heart disease), as well as due to the presence of micro- and macrovascular complications.

Objective: To investigate the relationship between COVID-19 infection and its severity in patients with diabetes mellitus.

Materials and methods: One-center retrospective study covering patients hospitalized in UMHAT Burgas AD, Burgas with a positive PCR test for SARS-CoV-2 infection, hospitalized from January 1 to January 31, 2021.

Results: The analysis included 368 patients with a mean age of 55 years, 62.3% of whom were male. During hospitalization, 73 patients died (19.8%). The most common concomitant diseases are diabetes mellitus (68.3%), obesity (42.6%) and hypertension (42.2%). Patients with diabetes mellitus had significantly higher mortality than those without diabetes mellitus, 22.3% and 14.1%, respectively (p = 0.04). Predictors of more severe course of SARS-CoV-2 infection in addition to gender, age and concomitant diseases are smoking, the presence of bilateral infiltrates, impaired renal function and accidental plasma glucose above 11.1 mmol / l.

Conclusion: The more severe course of SARS-CoV-2 infection in the diabetic population is probably due to older age, socio-economic factors, concomitant diseases, disorders of cell-mediated immunity. Patients with diabetes have an increased risk of death from any cause.


Diabetes mellitus, SARS-CoV-2

Full Text


Docherty AB, Harrison EM, Green CA, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:1985.

Lai PH, Lancet EA, Weiden MD, et al. Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City. JAMA Cardiol. 2020;2020:e202488.

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–34.

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichof D, Chen Y, Ogedegbe G, Hochman JS. Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–8.

Rezende LFM, Thome B, Schveitzer MC, Souza-Júnior PRB, Szwarcwald CL. Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil. Rev Saude Publica. 2020;54:50. -8787.2020054002596.

Saavedra JM. Angiotensin receptor blockers and COVID-19. Pharmacol Res. 2020;156:104832.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. -6736(20)30566-3

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. https://doi. org/10.1056/nejmoa2001017.



Font Size